In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions
Authors:
Preprint
Abstract
Conventional therapy for hereditary tyrosinemia type-1 (HT1) with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) delays and in some cases fails to prevent disease progression to liver fibrosis, liver failure, and activation of tumorigenic pathways. Here we demonstrate for the first time a cure of HT1 by direct, in vivo administration of a therapeutic lentiviral vector targeting the expression of a human fumarylacetoacetate hydrolase ( FAH ) transgene in the porcine model of HT1. This therapy was well tolerated and provided stable long-term expression of FAH in pigs with HT1. Genomic integration displayed a benign profile, with subsequent fibrosis and tumorigenicity gene expression patterns similar to wild-type animals as compared to NTBC-treated or diseased untreated animals. Indeed, the phenotypic and genomic data following in vivo lentiviral vector administration demonstrate comparative superiority over other therapies including ex vivo cell therapy and therefore support clinical application of this approach.Keywords
All Related Versions
- Published version: Nature Communications, 13 (1), 1.
This publication has 81 references indexed in Scilit:
- Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1Pediatric Drugs, 2019
- Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendationsGenetics in Medicine, 2017
- The Québec NTBC Study2017
- Liver Cancer in Tyrosinemia Type 12017
- Tyrosinemia type I treated by NTBC: How does AFP predict liver cancer?Molecular Genetics and Metabolism, 2006
- Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cellsJournal of Inherited Metabolic Disease, 2002
- The Pathophysiology and Treatment of Hereditary Tyrosinemia Type 1Seminars in Liver Disease, 2001
- NONTRANSPLANT TREATMENT OF TYROSINEMIAClinics in Liver Disease, 2000
- Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenaseThe Lancet, 1992
- On the enzymic defects in hereditary tyrosinemia.Proceedings of the National Academy of Sciences, 1977